Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium alginate + sodium bicarbonate + calcium carbonate (General Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- General Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zeroflux is an oral antacid and anti-reflux combination therapy containing sodium alginate, sodium bicarbonate, and calcium carbonate. It is primarily used for the symptomatic relief of gastroesophageal reflux disease (GERD), heartburn, acid regurgitation, and indigestion. Upon ingestion, the sodium alginate component reacts with gastric acid to form a viscous alginic acid gel raft that floats on top of the stomach contents, creating a physical barrier that prevents acid reflux into the esophagus. Concurrently, sodium bicarbonate and calcium carbonate act as antacids, neutralizing excess stomach acid to provide rapid relief from hyperacidity. Developed and marketed by General Pharmaceuticals, Zeroflux is approved for use in adults and children over 12 years of age.
- Brand names
- Zeroflux
- Other names
- calcium carbonate + sodium alginate + sodium bicarbonatesodium alginate + calcium carbonate + sodium bicarbonate
02
Targets
HCl (Hydrochloric acid)
Beyond the preview
Go deeper on sodium alginate + sodium bicarbonate + calcium carbonate (General Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium alginate + sodium bicarbonate + calcium carbonate (General Pharmaceuticals).